Publicaciones en colaboración con investigadores/as de University of Paris-Sorbonne (17)

2024

  1. Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

    Blood

  2. Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma

    Future Oncology, Vol. 20, Núm. 18, pp. 1221-1235

  3. Prevalence and Phenotypic Susceptibility to Doravirine of the HIV-1 Reverse Transcriptase V106I Polymorphism in B and Non-B Subtypes

    Journal of Infectious Diseases, Vol. 229, Núm. 6, pp. 1796-1802

  4. Rate of recurrence after discontinuing anticoagulation in patients with venous thromboembolism within 30 days after COVID-19 vaccine

    European Journal of Clinical Investigation

  5. Venous thromboembolism characteristics and outcomes among RIETE patients tested and untested for inherited thrombophilia

    Blood Advances, Vol. 8, Núm. 18, pp. 4950-4959

2023

  1. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  2. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.

    New England Journal of Medicine, Vol. 388, Núm. 11, pp. 1002-1014

2022

  1. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19

    The Lancet Oncology, Vol. 23, Núm. 7, pp. e334-e347

  2. Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus

    ESMO Open, Vol. 7, Núm. 2

  3. Outcome of Cancer-Associated Venous Thromboembolism Is More Favorable among Patients with Hematologic Malignancies than in Those with Solid Tumors

    Thrombosis and Haemostasis, Vol. 122, Núm. 9, pp. 1594-1602

  4. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

    Blood, Vol. 140, Núm. 11, pp. 1229-1253

2015

  1. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab

    Blood, Vol. 125, Núm. 5, pp. 775-783

2013

  1. Endothelial colony-forming cells from patients with paroxysmal nocturnal haemoglobinuria are not PIGA mutated

    British Journal of Haematology

  2. International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer

    Journal of Thrombosis and Haemostasis, Vol. 11, Núm. 1, pp. 71-80

2012

  1. Clostridium difficile Infection after Allogeneic Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, and Outcome

    Biology of Blood and Marrow Transplantation, Vol. 18, Núm. 8, pp. 1295-1301

  2. Increased infection rate after preemptive rituximab treatment for epstein-barr virus reactivation after allogeneic hematopoietic stem-cell transplantation

    Transplantation, Vol. 94, Núm. 8, pp. 879-883

  3. Long-term follow up after allogeneic stem cell transplantation in patients with severe aplastic anemia after cyclophosphamide plus antithymocyte globulin conditioning

    Haematologica, Vol. 97, Núm. 5, pp. 710-716